A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Polatuzumab vedotin (Primary) ; Bendamustine; Obinutuzumab; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 22 Nov 2017 Planned End Date changed from 28 Mar 2019 to 13 Jun 2019.
    • 30 Jun 2017 Accordin to a Roche media release, based on the resutls of this study the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for polatuzumab vedotin in combination with rituximab and bendamustine for the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL).
    • 25 Jun 2017 Updated results (n=65; data cut off 14 Nov 2016) presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top